Avadel Pharmaceuticals (AVDL) Total Debt (2016 - 2022)
Historic Total Debt for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $136.2 million.
- Avadel Pharmaceuticals' Total Debt fell 411.93% to $136.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $136.2 million, marking a year-over-year decrease of 411.93%. This contributed to the annual value of $142.4 million for FY2021, which is 1106.54% up from last year.
- Avadel Pharmaceuticals' Total Debt amounted to $136.2 million in Q3 2022, which was down 411.93% from $134.3 million recorded in Q2 2022.
- Avadel Pharmaceuticals' 5-year Total Debt high stood at $142.7 million for Q1 2022, and its period low was $1.9 million during Q2 2020.
- Moreover, its 5-year median value for Total Debt was $127.2 million (2019), whereas its average is $102.0 million.
- In the last 5 years, Avadel Pharmaceuticals' Total Debt plummeted by 9210.62% in 2020 and then surged by 730721.0% in 2021.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Total Debt stood at $125.2 million in 2018, then grew by 1.65% to $127.2 million in 2019, then increased by 0.76% to $128.2 million in 2020, then grew by 11.07% to $142.4 million in 2021, then fell by 4.33% to $136.2 million in 2022.
- Its Total Debt stands at $136.2 million for Q3 2022, versus $134.3 million for Q2 2022 and $142.7 million for Q1 2022.